share_log

Guggenheim Maintains Buy on Prime Medicine, Lowers Price Target to $20

Moomoo 24/7 ·  Mar 5 12:04

Guggenheim analyst Debjit Chattopadhyay maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $24 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment